Abstract
Applying Chinese medicine (CM) is an important strategy for malignant tumor treatment in China. One of the significant characteristics of CM is to treat diseases based on syndrome differentiation. For Western medicine, it is of important clinical significance to formulate guidelines for the diagnosis and treatment of cancer patients based on the characteristics of disease differentiation. In Chinese clinical practice, the combination of disease differentiation and syndrome differentiation is an important feature for cancer treatment in the past. Currently, molecular profiling and genomic analysis-based precision medicine optimizes the anticancer drug design and holds the greatest success in treating cancer patients. Therefore, we want to know which populations of cancer patients can benefit more from CM treatment if the theory of precision medicine is applied to CM clinical practice. So, we developed a novel diagnostic and therapeutic strategy “disease-syndrome differentiation-genomic profiling-prescriptions” for cancer patients by CM syndrome differentiation and precision medicine. As a result, this strategy has greatly enhanced the anti-tumor efficacy of CM and improved clinical outcomes for cancer patients with some gene mutations. Our idea will hopefully establish a novel approach for the inheritance and innovation of CM.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Yu YY, Zhu YJ, Zou Y, Xiao ZZ, Shi S, Liu YH, et al. Qing-Kai-Ling Injection acts better than Shen-Fu Injection in enhancing the antitumor effect of gefitinib in resistant non-small cell lung cancer models. Evid Based Complement Alternat Med 2021;2021:9911935.
Wang HQ, Zhang Z, Zhao YP, Li J, Chen K. Expression of HSP70 and P53 in malignant tumor tissues and its relationship to heat syndrome of TCM. Chin J Integr Tradit Chin West Med (Chin) 2004;24:897–900.
Gong BJ, Kao Y, Zhang C, Zhao H, Sun F, Gong Z. Exploring the pharmacological mechanism of the herb pair “HuangLian-GanJiang” against colorectal cancer based on network pharmacology. Evid Based Complement Alternat Med 2019;2019:2735050.
Sun DZ, Li SD, Liu Y, Zhang Y, Mei R, Yang MH. Differences in the origin of philosophy between Chinese medicine and Western medicine: exploration of the holistic advantages of Chinese medicine. Chin J Integr Med 2013;19:706–711.
Olivier M, Asmis R, Hawkins GA, Howard TD, Cox LA. The need for multi-omics biomarker signatures in precision medicine. Int J Mol Sci 2019;20:4781.
Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: an update and perspective. Drug Resist Updat 2021;59:100796.
Guo Y, Liu Z, Li K, Cao G, Sun C, Cheng G, et al. Paris polyphylla-derived saponins inhibit growth of bladder cancer cells by inducing mutant p53 degradation while up-regulating CDKN1A expression. Curr Urol 2018;11:131–138.
Jiang ZB, Wang WJ, Xu C, Xie YJ, Wang XR, Zhang YZ, et al. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer Lett 2021;515:36–48.
Yu M, Ren L, Liang F, Zhang Y, Jiang L, Ma W, et al. Effect of epiberberine from Coptis chinensis Franch on inhibition of tumor growth in MKN-45 xenograft mice. Phytomedicine 2020;76:153216.
Zhang Q, Wang X, Cao S, Sun Y, He X, Jiang B, et al. Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways. Biomed Pharmacother 2020;128:110245.
Wang J, Cai H, Liu Q, Xia Y, Xing L, Zuo Q, et al. Cinobufacini inhibits colon cancer invasion and metastasis via suppressing Wntβ-catenin signaling pathway and EMT. Am J Chin Med 2020;48:703–718.
Li L, Wang S, Yang X, Long S, Xiao S, Wu W, et al. Traditional Chinese medicine, Fuzheng Kang’ai Decoction, inhibits metastasis of lung cancer cells through the STAT3/MMP9 pathway. Mol Med Rep 2017;16:2461–2468.
Luo TT, Lu Y, Yan SK, Xiao X, Rong XL, Guo J. Network pharmacology in research of Chinese medicine formula: methodology, application and prospective. Chin J Integr Med 2020;26:72–80.
Santos LHS, Ferreira RS, Caffarena ER. Integrating molecular docking and molecular dynamics simulations. Methods Mol Biol 2019;2053:13–34.
Hossain R, Sarkar C, Hassan SMH, Khan RA, Arman M, Ray P, et al. In silico screening of natural products as potential inhibitors of SARS-CoV-2 using molecular docking simulation. Chin J Integr Med 2022;28:249–256.
Sun X, Zhang Y, Zhou Y, Lian X, Yan L, Pan T, et al. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Res 2022;50:D1324–D1333.
Sui Y, Li S, Zhao Y, Liu Q, Qiao Y, Feng L, Li S. Identification of a natural compound, sesamin, as a novel TRPM8 antagonist with inhibitory effects on prostate adenocarcinoma. Fitoterapia 2020;145:104631.
Jin J, Zhou M, Wang X, Liu M, Huang H, Yan F, et al. Triptolidenol, isolated from Tripterygium wilfordii, disrupted NF-κ B/COX-2 pathway by targeting ATP-binding sites of IKK β in clear cell renal cell carcinoma. Fitoterapia 2021;148:104779.
Luo H, Vong CT, Chen H, Gao Y, Lyu P, Qiu L, et al. Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine. Chin Med 2019;14:48.
Chen ST, Lee TY, Tsai TH, Lin YC, Lin CP, Shieh HR, et al. The traditional Chinese medicine Danggui Buxue Tang sensitizes colorectal cancer cells to chemoradiotherapy. Molecules 2016;21:1677.
Author information
Authors and Affiliations
Contributions
Yu SX was responsible for writing the manuscript; Liang ZM designed the thesis framework. Yu SX and Liang ZM made equal contributions to this work. Wu QB, Shou L, Huang XX, Zhu QR, Xie H, Mei RY, Zhang RN and Zhai XY collected materials; Xie T and Sui XB guided the manuscript.
Corresponding author
Additional information
Supported by the National Natural Science Foundation of China (Nos. 81874380 and 82022075, 81730108 and 81973635), and Zhejiang Province Science and Technology Project of TCM (No. 2021ZQ058)
Rights and permissions
About this article
Cite this article
Yu, Sx., Liang, Zm., Wu, Qb. et al. A Novel Diagnostic and Therapeutic Strategy for Cancer Patients by Integrating Chinese Medicine Syndrome Differentiation and Precision Medicine. Chin. J. Integr. Med. 28, 867–871 (2022). https://doi.org/10.1007/s11655-022-3671-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-022-3671-z